A Newly Approved Targeted Combination Therapy for KRAS-Mutant Low-Grade Serous Ovarian Cancer
This episode features Dr Rachel Grisham and Dr Kathleen Moore discussing the historical challenges associated with treating low-grade serous ovarian cancer and the recent transformational approved targeted therapy combination regimen of avutometinib and defactinib for KRAS-mutant LGSOC.
Decera Clinical Education Oncology Podcast · Rachel Grisham MD, Kathleen N. Moore MD MS FASCO
Audio is streamed directly from the publisher (afp-928689-injected.calisto.simplecastaudio.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In this episode, Dr Rachel Grisham and Dr Kathleen Moore discuss newly approved treatments for low-grade serous ovarian cancer (LGSOC) and how recent research has transformed the therapeutic landscape for these patients, including:
- Molecular distinctions between low-grade and high-grade serous ovarian cancer that can guide therapy selection
- The recently approved targeted therapy combination regimen of avutometinib and defactinib for KRAS-mutant LGSOC (RAMP 201)
- Promising future directions for patients with LGSOC based on ongoing studies such as RAMP 301 and CHAMELEON
Presenters:
Rachel Grisham, MD
Section Head of Ovarian Cancer
Memorial Sloan Kettering Cancer Center
Director Gynecologic Medical Oncology, MSKCC Westchester
New York, New York
Kathleen N. Moore, MD, MS, FASCO
Deputy Director and Cancer Therapeutics Co-Lead
Stephenson Cancer Center at the University of Oklahoma
Professor
Department of OB/Gyn
ASCO BOD
Oklahoma City, Oklahoma
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.